Pharma BD Deal Intelligence
Bristol-Myers Squibb Company / Amylin Pharmaceuticals
2012 · Acquisition/Merger · $5.3B · Complete
Announcement Sentiment
75
Strongly positive
Outcome Score
39
Underwhelmed — fell short of the thesis.
BMS acquired Amylin Pharmaceuticals for $5.3B for diabetes treatment portfolio.
Did it work? Outcome assessment
BMS / Amylin Pharmaceuticals: Partially Achieved (Score: 46/100)
Strategic verdict
Partially Achieved
Assessment window: 5yr post-close.
Key facts
- Announced Jun 29, 2012
- Closed Aug 09, 2012
- Deal value $5.3B
- Deal type Acquisition/Merger
- Therapeutic area Metabolic
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals